A detailed history of Nuveen Asset Management, LLC transactions in Chroma Dex Corp. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 66,114 shares of CDXC stock, worth $491,888. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,114
Previous 66,114 -0.0%
Holding current value
$491,888
Previous $180,000 33.89%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$2.44 - $4.32 $161,318 - $285,612
66,114 New
66,114 $180,000
Q2 2022

Aug 15, 2022

SELL
$1.59 - $2.7 $1.21 Million - $2.06 Million
-762,027 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.02 - $3.92 $36,240 - $70,328
-17,941 Reduced 2.3%
762,027 $1.88 Million
Q4 2021

Feb 14, 2022

SELL
$3.74 - $6.7 $7,614 - $13,641
-2,036 Reduced 0.26%
779,968 $3.13 Million
Q3 2021

Nov 12, 2021

BUY
$6.05 - $10.41 $2.53 Million - $4.35 Million
418,085 Added 114.88%
782,004 $5.3 Million
Q2 2021

Aug 16, 2021

BUY
$6.66 - $10.92 $1.38 Million - $2.26 Million
207,036 Added 131.97%
363,919 $3.59 Million
Q1 2021

May 17, 2021

BUY
$4.59 - $18.74 $69,465 - $283,611
15,134 Added 10.68%
156,883 $1.47 Million
Q4 2020

Feb 16, 2021

BUY
$3.93 - $5.5 $8,457 - $11,836
2,152 Added 1.54%
141,749 $681,000
Q3 2020

Nov 16, 2020

BUY
$4.01 - $5.56 $3,003 - $4,164
749 Added 0.54%
139,597 $560,000
Q2 2020

Aug 14, 2020

BUY
$3.0 - $5.52 $89,547 - $164,766
29,849 Added 27.38%
138,848 $637,000
Q1 2020

May 14, 2020

SELL
$2.54 - $4.75 $243 - $456
-96 Reduced 0.09%
108,999 $355,000
Q4 2019

Feb 14, 2020

SELL
$2.83 - $4.61 $5,546 - $9,035
-1,960 Reduced 1.76%
109,095 $470,000
Q3 2019

Nov 14, 2019

BUY
$3.83 - $4.72 $46,982 - $57,900
12,267 Added 12.42%
111,055 $437,000
Q2 2019

Aug 15, 2019

BUY
$3.71 - $4.83 $366,503 - $477,146
98,788 New
98,788 $460,000

Others Institutions Holding CDXC

About ChromaDex Corp.


  • Ticker CDXC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,350,896
  • Market Cap $509M
  • Description
  • ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...
More about CDXC
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.